Stocktoria
MANNATECH INC MTEX
Nasdaq · stock · Medicinal Chemicals & Botanical Products · website · IPO 1999-02-16
MANNATECH INC financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $108.0M | $117.9M | $132.0M | $137.2M | $159.8M | $151.4M | $157.7M | $173.6M | $176.7M | $180.3M |
| Gross profit | $81.0M | $91.5M | $102.9M | $104.1M | $125.6M | $115.9M | $126.2M | $139.1M | $141.0M | $143.7M |
| R&D expense | $800,000 | $700,000 | $800,000 | $1.0M | $1.2M | $800,000 | $1.1M | $1.0M | $1.2M | $1.4M |
| SG&A expense | $39.7M | $41.7M | — | — | — | — | — | — | — | — |
| Operating income | -$426,000 | $1.4M | -$964,000 | -$405,000 | $9.0M | $4.5M | $6.4M | -$90,000 | $2.5M | $661,000 |
| Income tax | $12.3M | $1.2M | $1.1M | $4.0M | -$950,000 | -$536,000 | $2.4M | $4.4M | $4.2M | -$369,000 |
| Net income | -$15.2M | $2.5M | -$2.2M | -$4.5M | $9.8M | $6.3M | $3.3M | -$3.9M | -$1.8M | -$586,000 |
| EPS (diluted) | $-8.00 | $1.32 | $-1.20 | $-2.35 | $4.71 | $2.77 | $1.35 | $-1.53 | $-0.66 | $-0.22 |
| Operating cash flow | -$3.0M | $2.3M | -$2.4M | -$2.6M | $10.8M | $6.0M | $4.9M | -$222,000 | $10.3M | -$23,000 |
| Free cash flow | -$4.3M | $2.0M | -$3.1M | -$3.7M | $10.1M | $5.1M | $3.7M | -$2.6M | $9.0M | -$2.3M |
| Cash & equivalents | $6.2M | $11.4M | $7.7M | $13.8M | $24.2M | $22.2M | $24.8M | $21.8M | $37.7M | $28.7M |
| Inventory | $10.1M | $10.4M | $14.5M | $14.7M | $12.0M | $12.8M | $10.2M | $12.8M | $9.4M | $12.0M |
| Total assets | $30.0M | $36.1M | $41.2M | $49.1M | $59.6M | $65.3M | $62.9M | $62.2M | $76.2M | $71.2M |
| Total liabilities | $35.2M | $27.4M | $30.7M | $35.0M | $35.2M | $39.4M | $35.6M | $36.9M | $36.0M | $32.3M |
| Shareholders' equity | -$5.2M | $8.6M | $10.5M | $14.2M | $24.4M | $26.0M | $27.3M | $25.3M | $40.2M | $38.9M |
Growth · year-over-year · Revenue CAGR -5.5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -8.3% | -10.7% | -3.8% | -14.1% | +5.5% | -4.0% | -9.1% | -1.8% | -2.0% | +0.0% |
| Net income growth | -711.0% | — | — | -145.6% | +57.2% | +90.4% | — | — | — | -110.0% |
| EPS growth | -706.1% | — | — | -149.9% | +70.0% | +105.2% | — | — | — | -110.3% |
| Free cash flow growth | -319.8% | — | — | -136.2% | +99.3% | +37.4% | — | -128.5% | — | -195.9% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.